Vol. 25 No. 3 (2021)
Endovascular Surgery

Comparison of neointimal healing with bioresorbable scaffolds and drug-eluting stents in patients with stable ischaemic heart disease

PDF (Русский)
  • S.S. Sapoznikov,
  • N.A. Galeeva,
  • I.S. Bessonov,
  • N.A. Musikhina,
  • T.I. Petelina,
  • A.O. Dyakova,
  • E.A. Gorbatenko
S.S. Sapoznikov
Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science, Tyumen
N.A. Galeeva
Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science, Tyumen
Bio
I.S. Bessonov
Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science, Tyumen
N.A. Musikhina
Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science, Tyumen
T.I. Petelina
Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science, Tyumen
A.O. Dyakova
Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science, Tyumen
E.A. Gorbatenko
Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science, Tyumen
DOI: https://doi.org/10.21688/1681-3472-2021-3-71-82

Published 2021-09-28

Keywords

  • coronary artery disease,
  • neointimal healing score,
  • optical coherence tomography

How to Cite

Sapoznikov, S., Galeeva, N., Bessonov, I., Musikhina, N., Petelina, T., Dyakova, A., & Gorbatenko, E. (2021). Comparison of neointimal healing with bioresorbable scaffolds and drug-eluting stents in patients with stable ischaemic heart disease. Patologiya Krovoobrashcheniya I Kardiokhirurgiya, 25(3), 71–82. https://doi.org/10.21688/1681-3472-2021-3-71-82

Copyright (c) 2021 Sapoznikov S.S., Galeeva N.A., Bessonov I.S., Musikhina N.A., Petelina T.I., Dyakova A.O., Gorbatenko E.A.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Aim. To examine the process of neointimal formation after bioresorbable scaffolds (BRS) implantation using optical coherence tomography (OCT) in patients with stable coronary artery disease (SCAD) and to determine relationship between neointimal healing and biochemical parameters of inflammation.
Methods. Patients with SCAD (n = 20) who were indicated for percutaneous coronary intervention (PCI) were enrolled. Patients were randomised into two groups as per the stent type. The treatment group comprised 10 patients who were implanted with BRS ABSORB (Abbott Laboratories, Abbott Park, USA) during PCI. The comparison group comprised 10 patients who were implanted with DES XIENCE (Abbott Laboratories, Abbott Park, USA) during PCI. All the patients underwent OCT imaging during PCI. Subsequently, 18 patients were subjected to coronary angiography with OCT imaging in 12 mon. The primary endpoint was the 12-month neointimal healing (NIH) score. Secondary endpoints were clinical outcomes (all-cause hospitalisation, myocardial infarction, probable stent thrombosis and death), OCT parameters at the 12-month follow-up and biochemical markers dynamics.
Results. Initial angiographic data analysis indicated a higher rate of balloon pre-dilatation (100% vs. 30%; р = 0,003) and post-dilatation (100% vs. 20% р = 0,001) in patients of the treatment group. According to OCT, the NIH score was significantly higher in the XIENCE group [0 versus 9,14 (1,63–17,55); р = 0,008] at 12 mon. There was no significant difference in the clinical outcomes between the two groups. However, the ABSORB group had an increased CD40 level after 4–5 d of PCI. In agreement with the results of correlation analysis, there was an inverse correlation between the NIH score and CD40 level at 4–5 d after PCI (r = −0,576; р = 0,016). The cut-off value of CD40 level at 4–5 d after PCI was 47,5 ng/mL for the detection of optimal neointimal healing.
Conclusion. In patients with SCAD, BRS demonstrated higher rate of neointimal healing than everolimus-coated stents. There was a registered inverse correlation of the NIH score with the CD40 level at 4–5 days after PCI. CD40 level > 47,5 ng/mL at 4–5 d after PCI increases the likelihood of optimal neointimal healing as per OCT data.

Received 19 February 2021. Revised 7 June 2021. Accepted 16 June 2021.

Funding: The study did not have sponsorship.

Conflict of interest: The authors declare no conflicts of interests.

Contribution of the authors
Conception and study design: I.S. Bessonov, N.A. Musikhina, T.I. Petelina
Data collection and analysis: S.S. Sapoznikov, I.S. Bessonov, N.А. Galeeva, A.O. Dyakova
Statistical analysis: S.S. Sapoznikov, E.A. Gorbatenko
Drafting the article: S.S. Sapoznikov, N.А. Galeeva, A.O. Dyakova
Critical revision of the article: I.S. Bessonov, S.S. Sapoznikov, E.A. Gorbatenko, N.A. Musikhina
Final approval of the version to be published: S.S. Sapoznikov, N.А. Galeeva, I.S. Bessonov, N.A. Musikhina, T.I. Petelina, A.O. Dyakova, E.A. Gorbatenko

PDF (Русский)

References

  1. Palmerini T., Benedetto U., Biondi-Zoccai G., Della Riva D., Bacchi-Reggiani L., Smits P.C., Vlachojannis G.J., Jensen L.O., Christiansen E.H., Berencsi K., Valgimigli M., Orlandi C., Petrou M., Rapezzi C., Stone G.W. Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2015;65(23):2496-2507. PMID: 26065988. https://doi.org/10.1016/j.jacc.2015.04.017
  2. Gada H., Kirtane A.J., Newman W., Sanz M., Hermiller J.B., Mahaffey K.W., Cutlip D.E., Sudhir K., Hou L., Koo K., Stone G.W. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). JACC Cardiovasc Interv. 2013;6(12):1263-1266. PMID: 24239202. https://doi.org/10.1016/j.jcin.2013.07.009
  3. Yamaji K., Räber L., Zanchin T., Spitzer E., Zanchin C., Pilgrim T., Stortecky S., Moschovitis A., Billinger M., Schönenberger C., Eberli F., Jüni P., Lüscher T.F., Heg D., Windecker S. Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial. Eur Heart J. 2016;37(45):3386-3395. PMID: 27578808. https://doi.org/10.1093/eurheartj/ehw343
  4. de Pommereau A., de Hemptinne Q., Varenne O., Picard F. Bioresorbable vascular scaffolds: Time to absorb past lessons or fade away? Arch Cardiovasc Dis. 2018;111(4):229-232. PMID: 29678390. https://doi.org/10.1016/j.acvd.2018.04.001
  5. Brie D., Penson P., Serban M.-C., Toth P.P., Simonton Ch., Serruys P.W., Banach M. Bioresorbable scaffold — A magic bullet for the treatment of coronary artery disease? Int J Cardiol. 2016;215:47-59. PMID: 27111160. https://doi.org/10.1016/j.ijcard.2016.04.027
  6. Ellis S.G., Kereiakes D.J., Metzger D.C., Caputo R.P., Rizik D.G., Teirstein P.S., Litt M.R., Kini A., Kabour A., Marx S.O., Popma J.J., McGreevy R., Zhang Z., Simonton C., Stone G.W.; ABSORB III Investigators. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015;373(20):1905-1915. PMID: 26457558. https://doi.org/10.1056/NEJMoa1509038
  7. Kang S.-H., Chae I.-H., Park J.-J., Lee H.S., Kang D.-Y., Hwang S.-S., Youn T.-J., Kim H.-S. Stent thrombosis with drug-eluting stents and bioresorbable scaffolds: evidence from a network meta-analysis of 147 trials. JACC Cardiovasc Interv. 2016;9(12):1203-1212. PMID: 27262860. https://doi.org/10.1016/j.jcin.2016.03.038
  8. Serruys P.W., Chevalier B., Dudek D., Cequier A., Carrié D., Iniguez A., Dominici M., van der Schaaf R.J., Haude M., Wasungu L., Veldhof S., Peng L., Staehr P., Grundeken M.J., Ishibashi Y., Garcia-Garcia H.M., Onuma Y. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015;385(9962):43-54. PMID: 25230593. https://doi.org/10.1016/S0140-6736(14)61455-0
  9. Wykrzykowska J.J., Kraak R.P., Hofma S.H., van der Schaaf R.J., Arkenbout E.K., IJsselmuiden A.J., Elias J., van Dongen I.M., Tijssen R.Y.G., Koch K.T., Baan J. Jr, Vis M.M., de Winter R.J., Piek J.J., Tijssen J.G.P., Henriques J.P.S.; AIDA Investigators. Bioresorbable scaffolds versus metallic stents in routine PCI. N Engl J Med. 2017;376(24):2319-2328. PMID: 28402237. https://doi.org/10.1056/NEJMoa1614954
  10. Прохорихин А.А., Фартаков Е.И., Малаев Д.У., Бойков А.А., Ойдуп-Оол С.В., Байструков В.И., Гражданкин И.О., Зубарев Д.Д., Покушалов Е.А., Кретов Е.И. Оценка эффективности и безопасности биодеградируемого каркаса Absorb: 6-месячные результаты регистра Gabi R: Russia. Патология кровообращения и кардиохирургия. 2019;23(1 Suppl 1):S26-S33. [Prokhorikhin A.A., Fartakov E.I., Malaev D.U., Boykov A.A., Oidup-Ool S.V., Baystrukov V.I., Grazhdankin I.O., Zubarev D.D., Pokushalov E.A., Kretov E.I. Efficacy and safety of bioresorbable vascular scaffold Absorb: 6-month outcomes of GABI-R: Russia registry. Patologiya krovoobrashcheniya i kardiokhirurgiya = Circulation Pathology and Cardiac Surgery. 2019;23(1 Suppl 1):S18-S25. (In Russ.)] http://doi.org/10.21688/1681-3472-2019-1S-S26-S33
  11. Stone G.W., Abizaid A., Onuma Y., Seth A., Gao R., Ormiston J., Kimura T., Chevalier B., Ben-Yehuda O., Dressler O., McAndrew T., Ellis S.G., Kereiakes D.J., Serruys P.W. Effect of technique on outcomes following bioresorbable vascular scaffold implantation: Analysis from the ABSORB trials. J Am Coll Cardiol. 2017;70(23):2863-2874. PMID: 29100704. https://doi.org/10.1016/j.jacc.2017.09.1106
  12. Gomez-Lara J., Brugaletta S., Ortega-Paz L., Vandeloo B., Moscarella E., Salas M., Romaguera R., Roura G., Ferreiro J.L., Teruel L., Gracida M., Windecker S., Serruys P.W., Gomez-Hospital J.-A., Sabaté M., Cequier A. Long-term coronary functional assessment of the infarct-related artery treated with everolimus-eluting bioresorbable scaffolds or everolimus-eluting metallic stents: Insights of the TROFI II trial. JACC Cardiovasc Interv. 2018;11(16):1559-1571. PMID: 29805111. https://doi.org/10.1016/j.jcin.2018.04.026
  13. Pleva L., Kusnierova P., Plevova P., Zapletalova J., Karpisek M., Faldynova L., Kovarova P., Kukla P. Increased levels of MMP-3, MMP-9 and MPO represent predictors of in-stent restenosis, while increased levels of ADMA, LCAT, ApoE and ApoD predict bare metal stent patency. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(4):586-594. PMID: 26365933. https://doi.org/10.5507/bp.2015.037
  14. Gabbasov Z., Kozlov S., Melnikov I., Byazrova S., Saburova O., Prokofieva L., Caprnda M., Curilla E., Gaspar L., Rodrigo L., Kruzliak P., Smirnov V. Novel biomarkers for coronary restenosis occurrence after drug-eluting stent implantation in patients with diabetes having stable coronary artery disease. Clin Appl Thromb Hemost. 2018;24(8):1308-1314. PMID: 29716394; PMCID: PMC6714775. https://doi.org/10.1177/1076029618771752
  15. Costa M.A., Simon D.I. Molecular basis of restenosis and drug-eluting stents. Circulation. 2005;111(17):2257-2273. PMID: 15867193. https://doi.org/10.1161/01.CIR.0000163587.36485.A7
  16. Ortega-Paz L., Brugaletta S., Sabaté M. Impact of PSP technique on clinical outcomes following bioresorbable scaffolds implantation. J Clin Med. 2018;7(2):27. PMID: 29415486; PMCID: PMC5852443. https://doi.org/10.3390/jcm7020027
  17. Бабунашвили А.М., Созыкин А.В. Оптическая когерентная томография коронарных артерий. Атлас для клинического применения. М.: Издательство АСВ, 2019. 148 с. [Babunashvili A.M., Sozykin A.V. Optical coherence tomography of the coronary arteries. Atlas for clinical use. Moscow: ASV Publ.; 2019. 148 p. (In Russ.)]
  18. García-García H.M., Muramatsu T., Nakatani Sh., Lee I.S., Holm N.R., Thuesen L., van Geuns R.-J., van der Ent M., Borovicanin V., Paunovic D., Onuma Y., Serruys P.W. Serial optical frequency domain imaging in STEMI patients: the follow-up report of TROFI study. Eur Heart J Cardiovasc Imaging. 2014;15(9):987-995. PMID: 24662443. https://doi.org/10.1093/ehjci/jeu042
  19. Serruys P.W., Onuma Y., Ormiston J.A., de Bruyne B., Regar E., Dudek D., Thuesen L., Smits P.C., Chevalier B., McClean D., Koolen J., Windecker S., Whitbourn R., Meredith I., Dorange C., Veldhof S., Miquel-Hebert K., Rapoza R., García-García H.M. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation. 2010;122(22):2301-2312. PMID: 21098436. https://doi.org/10.1161/CIRCULATIONAHA.110.970772
  20. Onuma Y., Sotomi Y., Shiomi H., Ozaki Y., Namiki A., Yasuda S., Ueno T., Ando K., Furuya J., Igarashi K., Kozuma K., Tanabe K., Kusano H., Rapoza R., Popma J.J., Stone G.W., Simonton C., Serruys P.W., Kimura T. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial. EuroIntervention. 2016;12(9):1090-1101. PMID: 27597270. https://doi.org/10.4244/EIJY16M09_01
  21. Gutiérrez-Chico J.L., van Geuns R.J., Regar E., van der Giessen W.J., Kelbaek H., Saunamáki K., Escaned J., Gonzalo N., di Mario C., Borgia F., Nüesch E., García-García H.M., Silber S., Windecker S., Serruys P.W. Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial. Eur Heart J. 2011;32(19):2454-2463. PMID: 21659439; PMCID: PMC3184229. https://doi.org/10.1093/eurheartj/ehr182
  22. Brugaletta S., Radu M.D., Garcia-Garcia H.M., Heo J.H., Farooq V., Girasis C., van Geuns R.J., Thuesen L., McClean D., Chevalier B., Windecker S., Koolen J., Rapoza R., Miquel-Hebert K., Ormiston J., Serruys P.W. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis. 2012;221(1):106-112. PMID: 22209268. https://doi.org/10.1016/j.atherosclerosis.2011.12.008
  23. Mori H., Atmakuri D.R., Torii S., Braumann R., Smith S., Jinnouchi H., Gupta A., Harari E., Shkullaku M., Kutys R., Fowler D., Romero M., Virmani R., Finn A.V. Very late pathological responses to cobalt-chromium everolimus-eluting, stainless steel sirolimus-eluting, and cobalt-chromium bare metal stents in humans. J Am Heart Assoc. 2017;6(11):e007244. PMID: 29150493; PMCID: PMC5721792. https://doi.org/10.1161/JAHA.117.007244
  24. Farb A., Burke A.P., Kolodgie F.D., Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation. 2003;108(14):1701-1706. PMID: 14504181. https://doi.org/10.1161/01.CIR.0000091115.05480.B0
  25. Finn A.V., Joner M., Nakazawa G., Kolodgie F., Newell J., John M.C., Gold H.K., Virmani R. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007;115(18):2435-2441. PMID: 17438147. https://doi.org/10.1161/CIRCULATIONAHA.107.693739
  26. Taniwaki M., Radu M.D., Zaugg S., Amabile N., Garcia-Garcia H.M., Yamaji K., Jørgensen E., Kelbæk H., Pilgrim T., Caussin C., Zanchin T., Veugeois A., Abildgaard U., Jüni P., Cook S., Koskinas K.C., Windecker S., Räber L. Mechanisms of very late drug-eluting stent thrombosis assessed by optical coherence tomography. Circulation. 2016;133(7):650-660. PMID: 26762519. https://doi.org/10.1161/CIRCULATIONAHA.115.019071
  27. Heeger C.H., Busjahn A., Hildebrand L., Fenski M., Lesche F., Meincke F., Kuck K.-H., Bergmann M.W. Delayed coverage of drug-eluting stents after interventional revascularisation of chronic total occlusions assessed by optical coherence tomography: the ALSTER-OCT-CTO registry. EuroIntervention. 2016;11(9):1004-1012. PMID: 25287264. https://doi.org/10.4244/EIJY14M10_01
  28. Serruys P.W., Chevalier B., Sotomi Y., Cequier A., Carrié D., Piek J.J., Van Boven A.J., Dominici M., Dudek D., McClean D., Helqvist S., Haude M., Reith S., de Sousa Almeida M., Campo G., Iñiguez A., Sabaté M., Windecker S., Onuma Y. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016;388(10059):2479-2491. PMID: 27806897. https://doi.org/10.1016/S0140-6736(16)32050-5
  29. Prati F., Romagnoli E., Gatto L., La Manna A., Burzotta F., Limbruno U., Versaci F., Fabbiocchi F., Di Giorgio A., Marco V., Ramazzotti V., Di Vito L., Trani C., Porto I., Boi A., Tavazzi L., Mintz G.S. Clinical impact of suboptimal stenting and residual intrastent plaque / thrombus protrusion in patients with acute coronary syndrome: The CLI-OPCI ACS Substudy (Centro per la Lotta Contro L'Infarto-Optimization of Percutaneous Coronary Intervention in Acute Coronary Syndrome). Circ Cardiovasc Interv. 2016;9(12):e003726. PMID: 27965297. https://doi.org/10.1161/CIRCINTERVENTIONS.115.003726
  30. Prati F., Romagnoli E., Burzotta F., Limbruno U., Gatto L., La Manna A., Versaci F., Marco V., Di Vito L., Imola F., Paoletti G., Trani C., Tamburino C., Tavazzi L., Mintz G.S. Clinical impact of OCT findings during PCI: The CLI-OPCI II Study. JACC Cardiovasc Imaging. 2015;8(11):1297-1305. PMID: 26563859. https://doi.org/10.1016/j.jcmg.2015.08.013
  31. Singh M.P., Sethuraman S.N., Ritchey J., Fiering S., Guha C., Malayer J., Ranjan A. In-situ vaccination using focused ultrasound heating and anti-CD-40 agonistic antibody enhances T-cell mediated local and abscopal effects in murine melanoma. Int J Hyperthermia. 2019;36(sup1):64-73. PMID: 31795832; PMCID: PMC6897315. https://doi.org/10.1080/02656736.2019.1663280
  32. Diaz-Rodriguez S., Rasser C., Mesnier J., Chevallier P., Gallet R., Choqueux C., Even G., Sayah N., Chaubet F., Nicoletti A., Ghaleh B., Feldman L.J., Mantovani D., Caligiuri G. Coronary stent CD31-mimetic coating favours endothelialization and reduces local inflammation and neointimal development in vivo. Eur Heart J. 2021;42(18):1760-1769. PMID: 33580685; PMCID: PMC8106951. https://doi.org/10.1093/eurheartj/ehab027
  33. Li G., Sanders J.M., Bevard M.H., Sun Z., Chumley J.W., Galkina E.V., Ley K., Sarembock I.J. CD40 ligand promotes Mac-1 expression, leukocyte recruitment, and neointima formation after vascular injury. Am J Pathol. 2008;172(4):1141-1152. PMID: 18349125; PMCID: PMC2276409. https://doi.org/10.2353/ajpath.2008.070633
  34. Willecke F., Tiwari S., Rupprecht B., Wolf D., Hergeth S., Hoppe N., Dufner B., Schulte L., Anto Michel N., Bukosza N., Marchini T., Jackel M., Stachon P., Hilgendorf I., Zeschky K., Schleicher R., Langer H.F., von Zur Muhlen C., Bode C., Peter K., Zirlik A. Interruption of classic CD40L-CD40 signalling but not of the novel CD40L-Mac-1 interaction limits arterial neointima formation in mice. Thromb Haemost. 2014;112(2):379-389. PMID: 24652469. https://doi.org/10.1160/TH13-08-0653
  35. Donners M.M.P.C., Beckers L., Lievens D., Munnix I., Heemskerk J., Janssen B.J., Wijnands E., Cleutjens J., Zernecke A., Weber C., Ahonen C.L., Benbow U., Newby A.C., Noelle R.J., Daemen M.J.A.P., Lutgens E. The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling. Blood. 2008;111(9):4596-4604. PMID: 18195092; PMCID: PMC5726330. https://doi.org/10.1182/blood-2007-05-088906
  36. Caixeta A., Campos C.M., Felix C., Chieffo A., Capranzano P., Kawamoto H., Tamburino C., Diletti R., de Ribamar Costa J. Jr., Onuma Y., van Geuns R.J., Bartorelli A.L., Colombo A., Tamburino C., Serruys P.W., Abizaid A. Predictors of long-term adverse events after Absorb bioresorbable vascular scaffold implantation: a 1,933-patient pooled analysis from international registries. EuroIntervention. 2019;15(7):623-630. PMID: 30375335. https://doi.org/10.4244/EIJ-D-16-00796
  37. Onuma Y., Serruys P.W., Muramatsu T., Nakatani S., van Geuns R.-J., de Bruyne B., Dudek D., Christiansen E., Smits P.C., Chevalier B., McClean D., Koolen J., Windecker S., Whitbourn R., Meredith I., Garcia-Garcia H.M., Veldhof S., Rapoza R., Ormiston J.A. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the Absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2014;7(12):1400-1411. PMID: 25523532. https://doi.org/10.1016/j.jcin.2014.06.016
  38. Lhermusier T., Carrie D., Cayla G., Fajadet J., Sainsous J., Elhadad S., Tarragano F., Chevalier B., Ranc S., Curinier C., Le Breton H., Koning R.; FRANCE ABSORB Investigators. Three-year clinical outcomes with the ABSORB bioresorbable vascular scaffold in real life: Insights from the France ABSORB registry. Catheter Cardiovasc Interv. 2020. PMID: 33211387. https://doi.org/10.1002/ccd.29369 [Epub ahead of print]
  39. Garcia-Garcia H.M., McFadden E.P., Farb A., Mehran R., Stone G.W., Spertus J., Onuma Y., Morel M.-A., van Es G.-A., Zuckerman B., Fearon W.F., Taggart D., Kappetein A.-P., Krucoff M.W., Vranckx P., Windecker S., Cutlip D., Serruys P.W.; Academic Research Consortium. Standardized end point definitions for coronary intervention trials: The Academic Research Consortium-2 consensus document. Eur Heart J. 2018;39(23):2192-2207. PMID: 29897428. https://doi.org/10.1093/eurheartj/ehy223